Intelligence for Rheumatologists

Active Clinical Trials in
Rheumatology in Brazil

Up-to-date overview of clinical trials recruiting patients in Brazil — automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centres.

Active trials

195

Sites in Brazil

Indications covered

Carregando mapa…

37 studyies found

Fase 2Artrite ReumatoideSíndrome de SjögrenMiopatias InflamatóriasEsclerose Sistêmica🇧🇷 9 sites in Brazil

An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases

Artiva Biotherapeutics, Inc.

📍 São Paulo, Brasília, Porto Alegre, Cuiabá👥 90 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Lúpus Eritematoso Sistêmico🇧🇷 13 sites in Brazil

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy

Viatris Innovation GmbH

📍 Belo Horizonte, Brasília, Juiz de Fora, Passo Fundo, Porto Alegre, Rio de Janeiro, Salvador, Santa Cecília, São Bernardo do Campo, São José do Rio Preto, São Paulo, Uberlândia👥 420 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Nefrite Lúpica🇧🇷 11 sites in Brazil

A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).

Novartis Pharmaceuticals

📍 Vitória, Salvador, São Luís, Belo Horizonte, Juiz de Fora, Curitiba, Recife, Porto Alegre, Santo André👥 462 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Lúpus Eritematoso Sistêmico🇧🇷 9 sites in Brazil

SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE

AbbVie

📍 Vitória, Salvador, Juiz de Fora, Curitiba, Porto Alegre, São José do Rio Preto, São Paulo👥 1000 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Miopatias Inflamatórias🇧🇷 9 sites in Brazil

A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

AstraZeneca

📍 Joinville, Juiz de Fora, Pelotas, Porto Alegre, Salvador, São José do Rio Preto, São Paulo👥 240 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Lúpus Eritematoso Sistêmico🇧🇷 7 sites in Brazil

A Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)

Novartis Pharmaceuticals

📍 Salvador, Belo Horizonte, Rio de Janeiro, Barretos, São Paulo👥 550 participants📅 Completion: 2030-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Lúpus Eritematoso Sistêmico🇧🇷 4 sites in Brazil

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy

AstraZeneca

📍 Porto Alegre, Ribeirão Preto, São Paulo👥 100 participants📅 Completion: 2028-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Lúpus Eritematoso Sistêmico🇧🇷 6 sites in Brazil

A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy.

AstraZeneca

📍 Belo Horizonte, Porto Alegre, Rio de Janeiro, Salvador, São Paulo👥 302 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite Psoriásica🇧🇷 6 sites in Brazil

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants With Active Psoriatic Arthritis

Janssen Research & Development, LLC

📍 Belo Horizonte, Porto Alegre, São José do Rio Preto, São Paulo👥 750 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Artrite Psoriásica🇧🇷 6 sites in Brazil

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

Takeda

📍 Juiz de Fora, Uberlândia, Curitiba, Porto Alegre, São José do Rio Preto, São Paulo👥 600 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Síndrome de Sjögren🇧🇷 3 sites in Brazil

A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Amgen

📍 Salvador, Curitiba, Porto Alegre👥 844 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Vasculite🇧🇷 1 site in Brazil

Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)

AstraZeneca

📍 São Paulo👥 14 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Nefrite Lúpica🇧🇷 1 site in Brazil

An Open-label Extension Study to Assess the Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Adult Participants With Lupus Nephritis Who Have Completed Study Treatment in the CVAY736K12301 Core Study (SIRIUS-LN Extension)

Novartis Pharmaceuticals

📍 Salvador👥 315 participants📅 Completion: 2030-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2, Fase 3Lúpus Eritematoso Sistêmico🇧🇷 21 sites in Brazil

A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Biogen

📍 Fortaleza, Vitória, Salvador, Brasília, Santo Ângelo, Belo Horizonte, Juiz de Fora, Rio de Janeiro, Lajeado, Porto Alegre, Porto Velho, São Bernardo do Campo, São Paulo, Valinhos👥 450 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Nefrite Lúpica🇧🇷 8 sites in Brazil

An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V

Novartis Pharmaceuticals

📍 Salvador, Belo Horizonte, Juiz de Fora, Barretos, São Paulo👥 240 participants📅 Completion: 2026-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2, Fase 3Esclerose Sistêmica🇧🇷 8 sites in Brazil

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)

GlaxoSmithKline

📍 Belo Horizonte, Curitiba, Juiz de Fora, Porto Alegre, Salvador, São Paulo👥 300 participants📅 Completion: 2029-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Vasculite🇧🇷 7 sites in Brazil

Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (I TRANSCEND)

Alexion Pharmaceuticals, Inc.

📍 Barretos, Belo Horizonte, Porto Alegre, Recife, São Paulo👥 75 participants📅 Completion: 2027-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Artrite Reumatoide🇧🇷 7 sites in Brazil

A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

AstraZeneca

📍 Juiz de Fora, Pelotas, Porto Alegre, Salvador, São Paulo👥 320 participants📅 Completion: 2027-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Síndrome de Sjögren🇧🇷 6 sites in Brazil

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

Immunovant Sciences GmbH

📍 Vitória, Salvador, Juiz de Fora, Curitiba, Porto Alegre👥 180 participants📅 Completion: 2028-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Esclerose Sistêmica🇧🇷 6 sites in Brazil

A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Novartis Pharmaceuticals

📍 Salvador, Curitiba, Porto Alegre, Sao Jose Rio Preto, São Paulo👥 200 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Nefrite Lúpica🇧🇷 5 sites in Brazil

A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).

Novartis Pharmaceuticals

📍 Salvador, Barretos, São Paulo👥 179 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Vasculite🇧🇷 4 sites in Brazil

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Novartis Pharmaceuticals

📍 Salvador, Barretos, São Paulo👥 126 participants📅 Completion: 2029-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Nefrite Lúpica🇧🇷 4 sites in Brazil

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)

Hoffmann-La Roche

📍 Salvador, Campinas, São Paulo👥 40 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Espondilite Anquilosante🇧🇷 4 sites in Brazil

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Merck Sharp & Dohme LLC

📍 Juiz de Fora, Curitiba, Rio de Janeiro, São Paulo👥 315 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Nefrite Lúpica🇧🇷 3 sites in Brazil

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

📍 São Paulo👥 89 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Esclerose Sistêmica🇧🇷 1 site in Brazil

A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis

Novartis Pharmaceuticals

📍 São Paulo👥 96 participants📅 Completion: 2028-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Outras Doenças Autoimunes🇧🇷 1 site in Brazil

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Incyte Corporation

📍 São Paulo👥 98 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Lúpus Eritematoso Sistêmico🇧🇷 4 sites in Brazil

A Phase 1, First-time-in-human, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), Healthy Participants of Chinese and Japanese Descent (Part C) and Participants With Interstitial Lung Disease Associated With Connective Tissue Disease (Part D)

GlaxoSmithKline

📍 Porto Alegre, Juiz de Fora, Salvador👥 142 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Outras Doenças Autoimunes🇧🇷 3 sites in Brazil

A Phase 1, Multicenter, Open-label Study of BMS-986515, Healthy Donor Allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

📍 Salvador, Porto Alegre, São Paulo👥 125 participants📅 Completion: 2029-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Artrite Reumatoide🇧🇷 1 site in Brazil

An Open-label, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Surovatamig Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus

AstraZeneca

📍 Porto Alegre👥 48 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Lúpus Eritematoso Sistêmico🇧🇷 11 sites in Brazil

A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus

GlaxoSmithKline

📍 Belo Horizonte, Cuiabá, Juiz de Fora, Passo Fundo, Porto Alegre, Salvador, São José do Rio Preto, São Paulo👥 350 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Síndrome de Sjögren🇧🇷 1 site in Brazil

TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE: A PROSPECTIVE RANDOMIZED STUDY

University of Sao Paulo General Hospital

📍 São Paulo👥 60 participants📅 Completion: 2029-09

View details →Refer patient →ClinicalTrials.gov ↗

OBSERVATIONALDoenças Autoinflamatórias🇧🇷 1 site in Brazil

Comparison and Performance of Kobayashi and Kawanet IVIg Resistance Scores in a Multi-centric European and North Indian Cohort of KaWasaki dIsease (the KIWI Study)

Meyer Children's Hospital IRCCS

📍 Rio de Janeiro👥 103 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

OBSERVATIONALMiopatias Inflamatórias🇧🇷 1 site in Brazil

Optimizing Treatment on Idiopathic Inflammatory Myopathies

University of Sao Paulo

📍 São Paulo👥 60 participants📅 Completion: 2024-05

View details →Refer patient →ClinicalTrials.gov ↗

OBSERVATIONALOutras Doenças Autoimunes🇧🇷 1 site in Brazil

Prognostic Factors of Efficacy in Corticoid and Anesthetic Joint Infiltration for the Treatment of Patients with Low Back Pain Secondary to Zygapophyseal Osteoarthritis: a Prospective Cohort Study

Hospital Israelita Albert Einstein

📍 São Paulo👥 147 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

OBSERVATIONALEspondilite Anquilosante🇧🇷 1 site in Brazil

Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis

University of Siena

📍 São Paulo👥 3500 participants📅 Completion: 2026-08

View details →Refer patient →ClinicalTrials.gov ↗

OBSERVATIONALLúpus Eritematoso Sistêmico🇧🇷 1 site in Brazil

Prospective, Observational Study in Participants With Active Systemic Lupus Erythematosus (SLE) (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and At Least 2 Immunosuppressants

Bristol-Myers Squibb

📍 São Paulo👥 223 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Active Clinical Trials inRheumatology in Brazil

An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy

A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).

SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE

A Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)

A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants With Active Psoriatic Arthritis

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)

An Open-label Extension Study to Assess the Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Adult Participants With Lupus Nephritis Who Have Completed Study Treatment in the CVAY736K12301 Core Study (SIRIUS-LN Extension)

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)

Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (I TRANSCEND)

A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

A Phase 1, Multicenter, Open-label Study of BMS-986515, Healthy Donor Allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases

An Open-label, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Surovatamig Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus

A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus

TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE: A PROSPECTIVE RANDOMIZED STUDY

Comparison and Performance of Kobayashi and Kawanet IVIg Resistance Scores in a Multi-centric European and North Indian Cohort of KaWasaki dIsease (the KIWI Study)

Optimizing Treatment on Idiopathic Inflammatory Myopathies

Prognostic Factors of Efficacy in Corticoid and Anesthetic Joint Infiltration for the Treatment of Patients with Low Back Pain Secondary to Zygapophyseal Osteoarthritis: a Prospective Cohort Study

Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis

Prospective, Observational Study in Participants With Active Systemic Lupus Erythematosus (SLE) (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and At Least 2 Immunosuppressants

Questions or requests?

Active Clinical Trials in
Rheumatology in Brazil